2023
DOI: 10.1093/eurjpc/zwad125.226
|View full text |Cite
|
Sign up to set email alerts
|

Hypertension awareness and control in CHD patients from 27 countries. Preliminary results of the ESC-EORP EUROASPIRE V survey

Abstract: Funding Acknowledgements Type of funding sources: Other. Main funding source(s): The following companies have supported the EORP programme: Amgen, Eli Lilly, Pfizer, Sanofi, Ferrer and Novo Nordisk. The sponsors had no role in the design, data collection, data analysis, data interpretation, decision to publish, or writing the manuscript. Background Hypertension is a highly prevalent cardiovascular risk factor, and yet a large… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles